Related Experiment Video
Updated: Jun 9, 2025
13:19
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.5K
An Antagonist Antibody That Inhibits Cancer Cell Growth In Vitro through RACK1
Ji Hoe Kim1, Eun Ji Lee1, Kyung Ho Han1
1Department of Biological Sciences and Biotechnology, Hannam University, Daejeon 34054, Republic of Korea.
Pharmaceuticals (Basel, Switzerland)
|October 26, 2024
Summary
Researchers developed a new method to screen for antibodies that inhibit cancer cell growth. An antibody targeting RACK1 effectively suppressed tumor cell proliferation, offering a potential new cancer therapy.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumorigenesis involves dysregulation of cell cycle control.
- Identifying novel therapeutic targets for cancer is critical.
- Antibodies can be developed to modulate cellular processes.
Purpose of the Study:
- To develop a novel antibody screening method.
- To identify antibodies that suppress cancer cell proliferation and induce apoptosis.
- To investigate RACK1 as a potential therapeutic target.
Main Methods:
- Utilized an autocrine signaling system with lentivirus for antibody screening.
- Employed Fluorescence-Activated Cell Sorting (FACS) assays and cell cycle analysis.
- Inhibited tumor growth in vitro using antibody-based cell cycle arrest.
Main Results:
- Identified Receptor for Activated C Kinase 1 (RACK1) as a key regulator of cancer cell growth.
- Selected the H9 antibody targeting RACK1 from a human antibody library.
- Demonstrated that the H9 antibody effectively suppressed cancer cell proliferation by inhibiting RACK1 function.
Conclusions:
- RACK1 plays a critical role in tumor cell cycling and is a potential therapeutic target.
- The H9 antibody shows promise as a novel therapeutic candidate for cancer treatment.
- Further development of RACK1-targeting antibodies could lead to new cancer therapies.
More Related Videos
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
7.9K
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
3.5K
Related Concept Videos
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
01:27Tumor Immunotherapy
486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K